Intellia Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Good afternoon. Thanks for joining us for another session of the 42nd JPMorgan Healthcare Conference. I'm Brian Cheng. I'm one of the senior biotech analysts here at the firm. I'm joined by my associate, John Kim, who is also the audience.
On the stage we have Intellia's management team. I'll pass the mike to John Leonard for a short presentation, followed by a live audience Q&A. John, the stage is yours.
Thank you, Brian. So it's a real pleasure to be here to tell the story of Intellia. And I've got two of my colleagues, Glenn Goddard, our CFO, in the end there; and David Lebwohl, who is our Chief Medical Officer for any of the questions. They'll participate in some of the things that [are] --
I'll be making some forward-looking statements today. There's the disclaimer that we make available.
The company is approaching its 10th year. And it was formed shortly after some seminal work that was done in the CRISPR
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
